Login / Signup

Reduced doses of emicizumab achieve good efficacy: Results from a national-wide multicentre real-world study in China.

Yuan XuYing WangRunhui WuChangcheng ZhengLi ZhangWeiqun XuXiaoqin FengHua WangXiangshan CaoLiya HeTianyang XueMingwei JinBingshou XieJing LingLirong SunRui SuHongbo ChengYongjun FangMan-Chiu PoonXiaohong SunLei ZhangFeng XueRenchi Yang
Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2024)
This is the largest study describing patients with HA receiving emicizumab prophylaxis on variant dose regimens in China. We confirmed that nonstandard dose is efficacious and can be considered where full-dose emicizumab is ill affordable.
Keyphrases
  • clinical trial
  • randomized controlled trial
  • quality improvement
  • cross sectional
  • study protocol
  • double blind